List of Excipients in Branded Drug IMATINIB MESYLATE

« Back to Dashboard

Generic Drugs Containing IMATINIB MESYLATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	imatinib mesylate	0054-0248	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	imatinib mesylate	0054-0248	CROSPOVIDONE
Hikma Pharmaceuticals USA Inc	imatinib mesylate	0054-0248	FERRIC OXIDE RED
Hikma Pharmaceuticals USA Inc	imatinib mesylate	0054-0248	FERRIC OXIDE YELLOW
Hikma Pharmaceuticals USA Inc	imatinib mesylate	0054-0248	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	imatinib mesylate	0054-0248	POLYETHYLENE GLYCOL

What are the Most Frequently-Used Excipients in IMATINIB MESYLATE?

# Of NDCs	Excipient
16	CELLULOSE, MICROCRYSTALLINE
4	COPOVIDONE K25-31
4	CROSCARMELLOSE SODIUM
29	CROSPOVIDONE
6	FD&C YELLOW NO. 6
30	FERRIC OXIDE RED

Imatinib Mesylate Excipient Strategy and Commercial Opportunities

Last updated: September 30, 2026

Imatinib mesylate is a mature, high-volume oncology generic with low active-ingredient differentiation and meaningful formulation opportunities. The core commercial openings are pediatric liquid and dispersible dosage forms, taste-masked products, lower-cost robust tablets, supply-chain improvements, and formulations adapted to markets with limited access to oncology medicines. The principal constraints are bioequivalence, dose flexibility, imatinib stability, powder handling, and limited patent protection for conventional excipient combinations.

What is the current commercial position of imatinib mesylate?

Imatinib mesylate is the mesylate salt of imatinib, a tyrosine kinase inhibitor originally commercialized by Novartis as Gleevec in the United States and Glivec in many other markets. It is approved for several hematologic malignancies and gastrointestinal stromal tumor indications, including Philadelphia chromosome-positive chronic myeloid leukemia and KIT-positive GIST.

The drug is commercially mature:

Parameter	Position
Reference product	Gleevec/Glivec
Original developer	Novartis
Active ingredient	Imatinib mesylate
Main dosage form	Immediate-release film-coated tablets
Common strengths	100 mg and 400 mg
Primary regulatory route for generics	ANDA, with applicable patent certification
Main markets	United States, Europe, India, China, Latin America, and other regulated and emerging markets
Competitive status	Multiple generic manufacturers
Principal commercial challenge	Price erosion and limited differentiation
Main formulation opportunity	Pediatric and patient-friendly oral dosage forms

Gleevec sales reached approximately $4.7 billion in 2015 before broader generic competition in the United States, according to Novartis annual-report disclosures. Current originator revenue is materially lower because generic imatinib has entered major markets (Novartis, 2016).

What excipients are used in imatinib mesylate tablets?

The reference product uses conventional direct-compression or dry-granulation excipients. U.S. labeling identifies lactose monohydrate, microcrystalline cellulose, crospovidone, colloidal silicon dioxide, and magnesium stearate in the tablet core. The film coating contains hypromellose and colorants, including iron oxides, with talc used as a coating component in the labeled formulation (FDA, 2023).

A representative excipient architecture is:

Formulation function	Typical excipient options	Strategic purpose
Diluent	Lactose monohydrate, microcrystalline cellulose, mannitol, dibasic calcium phosphate	Tablet mass, compressibility, dose uniformity
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Rapid tablet breakup
Glidant	Colloidal silicon dioxide	Powder flow and content uniformity
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection and tooling protection
Binder	Povidone, copovidone, pregelatinized starch	Granule and tablet strength
Film former	Hypromellose, polyvinyl alcohol	Appearance, handling, swallowability
Opacifier or colorant	Titanium dioxide where permitted, iron oxides	Identification and light protection
Taste-masking agent	Coating polymers, ion-exchange resins, lipids, flavors	Pediatric and dispersible products
Suspending agent	Xanthan gum, hydroxypropyl cellulose, sodium carboxymethylcellulose	Oral liquid uniformity
Preservative	Product-specific system	Microbial control in aqueous liquids

The formulation target is not simply a hard tablet. Imatinib products must maintain rapid and reproducible release while controlling friability, tablet weight, dose uniformity, and degradation during storage.

Which excipient risks are most important for imatinib mesylate?

Solubility and pH sensitivity

Imatinib mesylate has pH-dependent solubility. Formulation changes that alter microenvironmental pH, wetting, or salt conversion can change dissolution and exposure. Alkaline excipients, poorly controlled buffering systems, and hydrophobic lubricants require particular scrutiny.

A developer should evaluate:

• Dissolution across acidic, intermediate, and near-neutral media.
• Salt integrity during granulation and compression.
• Particle-size distribution of the active pharmaceutical ingredient.
• Excipient-driven changes in wetting and disintegration.
• Stability under high humidity.
• Compatibility with the mesylate salt.

High-dose tablet burden

A 400 mg strength creates a relatively large tablet when combined with excipients. Excessive tablet mass can reduce patient acceptability and increase manufacturing cost. High-load formulations using microcrystalline cellulose, mannitol, or co-processed excipients can reduce unit size, but they may affect tensile strength and dissolution.

Dose uniformity at lower strengths

The 100 mg strength is important for dose titration, pediatric dosing, adverse-event management, and patients requiring nonstandard daily doses. Low-dose uniformity becomes more difficult when the active is poorly distributed or when a large fraction of the tablet consists of coarse excipient particles.

Bitter taste and pediatric use

Imatinib is unsuitable for many children in conventional tablets because of swallowing difficulty and bitterness. A dispersible tablet or oral suspension must control both the initial bitter taste and the lingering aftertaste. Simple sweetening is unlikely to provide adequate masking.

Humidity and physical stability

Hygroscopic excipients, porous tablet structures, and inadequate packaging can increase moisture uptake. Packaging opportunities include high-barrier blister systems, desiccant-containing bottles, and unit-dose packs. Stability should be assessed under ICH long-term and accelerated conditions, with emphasis on assay, related substances, dissolution, and physical integrity (ICH, 2003; ICH, 2023).

What formulation opportunities exist for imatinib mesylate?

Pediatric oral liquid

A ready-to-use oral suspension would address a defined clinical need. The product would need:

• Uniform drug concentration throughout shelf life.
• Sedimentation that is readily resuspendable.
• Acceptable microbial control.
• Chemical stability in an aqueous vehicle.
• Taste masking without impairing absorption.
• A calibrated dosing device.
• Compatibility with nasogastric or feeding-tube administration where clinically relevant.

A dry powder for reconstitution can reduce chemical degradation during storage. It also lowers shipping weight and may improve global distribution. The commercial tradeoff is the need for reconstitution instructions, container headspace control, and a validated in-use period.

Dispersible or orally disintegrating tablet

A dispersible tablet could provide a lower-cost alternative to a liquid. Suitable design options include:

• Crospovidone-rich fast-disintegrating matrices.
• Mannitol-based tablets for mouthfeel.
• Polymer or lipid taste-masking layers.
• Multiparticulates or coated granules.
• Low-force compression followed by protective film coating.

An orally disintegrating tablet has to balance rapid oral breakup against the bitter taste released during disintegration. A conventional ODT without adequate taste masking may have poor patient acceptance despite favorable disintegration data.

Scored and dose-flexible tablets

A scored 100 mg tablet can support individualized dosing and pediatric titration. The commercial value is higher where physicians use weight-based dosing or adjust therapy for toxicity, hepatic impairment, drug interactions, or treatment response.

A split-tablet strategy requires demonstration of dose uniformity, subdivision performance, friability, and stability after splitting. Tablet scoring can create a useful product distinction but usually does not provide strong standalone patent protection.

High-speed, low-cost generic tablet

For the mature adult market, the most defensible opportunity may be manufacturing economics rather than a novel dosage form. Relevant levers include:

• Direct compression with a robust excipient platform.
• Continuous manufacturing.
• Lower-cost, globally qualified excipient sources.
• Reduced coating weight.
• High-throughput blister packaging.
• Improved tooling life through lubricant optimization.
• Reduced tablet mass without loss of mechanical strength.

This strategy is commercially attractive in tender markets, but it is exposed to aggressive generic price competition.

What patents protect imatinib mesylate formulations?

The original composition-of-matter patent estate has expired in the United States. U.S. Patent No. 5,521,184, associated with the imatinib chemical series, had a listed expiration in 2015 after applicable patent-term adjustments or extensions. A later Novartis patent covering crystalline forms of imatinib mesylate was listed with an expiration in 2022. These dates removed the primary U.S. barriers to conventional generic tablets (FDA, 2024; USPTO, 2024).

The remaining formulation opportunity is generally narrower:

IP category	Protection potential	Commercial relevance
New salt or crystalline form	Low to moderate, depending on genuine technical difference	May affect solid-state control and stability
Conventional tablet with common excipients	Low	Usually vulnerable to obviousness and lack of novelty challenges
Specific pediatric liquid	Moderate	Requires strong stability, taste, and performance data
Taste-masked multiparticulate	Moderate to high	Can protect a defined architecture and release profile
Manufacturing process	Moderate	Stronger when it solves a reproducible scale-up problem
Packaging and moisture-control system	Low to moderate	Useful as a secondary barrier
New method of use	Potentially moderate	Limited by prior art and approved-label scope
Combination product	Potentially moderate	Depends on clinical and regulatory support

A formulation patent should claim measurable performance, not merely a list of familiar excipients. Useful claim elements may include a defined particle-size range, coating thickness, dissolution profile, reconstitution stability, taste-masking system, moisture limit, or manufacturing sequence.

What is the FDA regulatory status of generic imatinib?

Generic imatinib tablets are approved through the ANDA pathway when they demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. The applicant must address active ingredient, dosage form, strength, route, labeling, impurities, manufacturing controls, and stability.

Key regulatory considerations include:

1. Demonstrating equivalent exposure under FDA bioequivalence requirements.
2. Matching the reference product’s immediate-release performance.
3. Supporting a formulation that does not materially alter absorption.
4. Addressing patent certifications under the Hatch-Waxman framework.
5. Providing stability data for the proposed container-closure system.
6. Demonstrating manufacturing control for content uniformity and dissolution.

A new pediatric liquid or dispersible product may require a different regulatory strategy if it is not pharmaceutically equivalent to the reference tablet. Depending on the product design, the applicant could face a 505(b)(2) pathway rather than a straightforward ANDA. The route affects development cost, clinical requirements, labeling flexibility, and patent exposure (FDA, 2024).

When did imatinib mesylate lose U.S. exclusivity?

U.S. generic entry followed expiration of the core imatinib patent estate. Teva announced U.S. generic imatinib availability in 2016, while other manufacturers entered over time. The practical loss of exclusivity occurred in stages because patent expiration, tentative approvals, settlements, manufacturing readiness, and supply agreements affected actual launch timing.

Event	Approximate timing
U.S. Gleevec approval	2001
Core compound patent expiration	2015
First broad U.S. generic launch activity	2016
Later crystal-form patent expiration	2022
Current status	Mature generic market

The market should be analyzed by jurisdiction. European, Indian, Chinese, and Latin American patent and regulatory timelines were not identical to the U.S. timeline. A product cleared in one region may still face local patent, registration, manufacturing, or procurement barriers elsewhere.

What generic entry risks exist for a new imatinib product?

The principal risks are commercial rather than basic patent risk.

Price erosion

Multiple suppliers can compress net prices rapidly. A new tablet with the same strengths and no meaningful supply advantage may require a low-cost manufacturing model to achieve acceptable returns.

Reference-product supply and bioequivalence

Variability in active-particle properties, excipient grade, and compression behavior can generate dissolution differences. An apparently simple formulation may require extensive development work to reproduce reference performance.

Pediatric product competition

Pediatric formulations can command better pricing, but the addressable market is smaller. The product must deliver clear advantages in taste, dosing accuracy, storage, or administration.

Procurement concentration

Government tenders and hospital systems may prioritize price, continuity of supply, and local manufacturing. A technically differentiated product may not win without a reliable supply record.

Regulatory fragmentation

A formulation that qualifies as an ANDA in the United States may require additional clinical or bridging work in other jurisdictions. Pediatric liquid products can face different preservative, flavor, labeling, and dosing-device requirements.

Which companies are challenging the imatinib market?

The market includes originator-linked supply from Novartis and generic suppliers such as Teva and other regional manufacturers. Generic competition is fragmented across the United States, Europe, India, China, and emerging markets. The most relevant competitive dimensions are:

• Lowest sustainable cost per tablet.
• Reliable supply of imatinib mesylate API.
• Regulatory approvals across multiple markets.
• Pediatric dosage-form capability.
• Tender access and local distribution.
• Ability to manage recalls and pharmacovigilance.
• Manufacturing scale and quality history.

A new entrant is more likely to create value through a differentiated dosage form, regional access strategy, or supply reliability than through another standard 100 mg or 400 mg tablet.

How strong is the imatinib mesylate patent estate?

The patent estate is weak for ordinary generic tablets because the core composition-of-matter and important crystalline-form barriers have expired in the United States. New patent value is more likely in a targeted product claim covering pediatric administration, taste masking, controlled reconstitution, a specific solid form, or a reproducible manufacturing process.

Patent strength should be assessed against four questions:

1. Does the claim cover a clinically useful product?
2. Does the formulation solve a measurable technical problem?
3. Can an alternative excipient system avoid the claim?
4. Can the patent support enforceable infringement evidence?

A broad claim to lactose, cellulose, crospovidone, and magnesium stearate is unlikely to provide durable exclusivity. A claim tied to a specific dissolution window, stability profile, taste-masking structure, and manufacturing process is more defensible if supported by comparative data.

What licensing and partnering opportunities exist?

Licensing opportunities are concentrated in technology and distribution rather than the basic molecule. Potential transactions include:

• Taste-masking platforms for pediatric oncology products.
• Oral-liquid vehicles with validated stability.
• Coated multiparticulate technology.
• Continuous manufacturing technology.
• High-barrier packaging and dosing devices.
• Regional commercialization rights.
• API supply and dual-source agreements.
• Hospital and government tender partnerships.

A formulation license should be evaluated against the small market size of pediatric imatinib and the broad availability of standard tablets. Milestone structures should reflect actual regulatory value, not only patent filing activity.

Key Takeaways

• Imatinib mesylate is a mature generic market with limited value in undifferentiated tablets.
• The strongest excipient opportunities are pediatric liquids, dispersible tablets, taste-masked multiparticulates, and lower-mass dose-flexible tablets.
• Lactose, microcrystalline cellulose, crospovidone, colloidal silicon dioxide, and magnesium stearate are established reference-product excipients.
• pH-dependent solubility, salt integrity, bitterness, moisture sensitivity, and dissolution are the main formulation risks.
• U.S. core patent barriers have expired, and conventional tablet formulations have limited new patent value.
• Commercial differentiation is more likely to come from patient usability, supply reliability, regional access, and manufacturing cost.
• A pediatric or nonstandard dosage form may require a 505(b)(2) strategy rather than a simple ANDA.
• Generic launch economics depend on price erosion, tender access, API supply, and regulatory coverage across jurisdictions.

FAQs

Can imatinib mesylate be formulated as an oral suspension?

Yes. A suspension can improve pediatric administration, but it requires validated taste masking, uniformity, resuspendability, chemical stability, microbial control, and an appropriate dosing device.

Which excipient is best for masking imatinib bitterness?

No single excipient is universally optimal. Polymer-coated particles, ion-exchange resins, lipid barriers, and multiparticulate systems generally provide more reliable masking than sweeteners alone.

Is a 400 mg imatinib tablet commercially attractive?

It can be attractive in high-volume generic markets, but standard 400 mg tablets face intense price competition. The main advantages must come from manufacturing cost, supply reliability, tablet-size reduction, or regional procurement access.

Can a new imatinib formulation receive independent patent protection?

Yes, but protection is more plausible for a defined pediatric, taste-masked, liquid, multiparticulate, solid-state, or manufacturing technology than for a conventional tablet using standard excipients.

Does imatinib mesylate have biosimilar competition?

No. Imatinib mesylate is a small-molecule drug, so competitors are regulated as generics or, for certain reformulated products, under pathways such as 505(b)(2). Biosimilar rules apply to biologic products, not imatinib.

References

1. Food and Drug Administration. (2023). Gleevec (imatinib mesylate) prescribing information. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

3. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products.

4. International Council for Harmonisation. (2023). Q1A(R2) and related stability guidance. International Council for Harmonisation.

5. Novartis AG. (2016). Annual report 2015. Novartis.

6. United States Patent and Trademark Office. (2024). Patent Center and patent term information for U.S. Patent Nos. 5,521,184 and 6,894,051. U.S. Department of Commerce.